PTC Therapeutics (PTCT)
NASDAQ:PTCT
Want to see PTCT full AI Analyst Report?
Total Valuation
PTC Therapeutics has a market cap or net worth of $5.93B. The enterprise value is $5.49B.
Market Cap$5.93B
Enterprise Value$5.49B
Share Statistics
PTC Therapeutics has 82,949,340 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding82,949,340
Owned by Insiders1.44%
Owned by Institutions27.26%
Financial Efficiency
PTC Therapeutics’s return on equity (ROE) is -3.32 and return on invested capital (ROIC) is 37.39%.
Return on Equity (ROE)-3.32
Return on Assets (ROA)0.23
Return on Invested Capital (ROIC)37.39%
Return on Capital Employed (ROCE)0.44
Revenue Per Employee1.84M
Profits Per Employee726.99K
Employee Count939
Asset Turnover0.59
Inventory Turnover0.90
Valuation Ratios
The current PE Ratio of PTC Therapeutics is ―. PTC Therapeutics’s PEG ratio is -0.03.
PE Ratio―
PS Ratio3.49
PB Ratio-29.43
Price to Fair Value-29.43
Price to FCF8.60
Price to Operating Cash Flow-27.06
PEG Ratio-0.03
Income Statement
In the last 12 months, PTC Therapeutics had revenue of 1.73B and earned 682.64M in profits. Earnings per share was 8.58.
Revenue1.73B
Gross Profit1.66B
Operating Income856.51M
Pretax Income696.62M
Net Income682.64M
EBITDA887.66M
Earnings Per Share (EPS)8.58
Cash Flow
In the last 12 months, operating cash flow was -217.95M and capital expenditures -11.01M, giving a free cash flow of -228.96M billion.
Operating Cash Flow-217.95M
Free Cash Flow-228.96M
Free Cash Flow per Share-2.76
Dividends & Yields
PTC Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.15
52-Week Price Change52.19%
50-Day Moving Average68.47
200-Day Moving Average65.51
Relative Strength Index (RSI)58.95
Average Volume (3m)1.02M
Important Dates
PTC Therapeutics upcoming earnings date is Jul 30, 2026, After Close (Confirmed).
Last Earnings DateMay 7, 2026
Next Earnings DateJul 30, 2026
Ex-Dividend Date―
Financial Position
PTC Therapeutics as a current ratio of 2.35, with Debt / Equity ratio of -218.93%
Current Ratio2.35
Quick Ratio2.27
Debt to Market Cap0.07
Net Debt to EBITDA-0.55
Interest Coverage Ratio5.63
Taxes
In the past 12 months, PTC Therapeutics has paid 13.97M in taxes.
Income Tax13.97M
Effective Tax Rate0.02
Enterprise Valuation
PTC Therapeutics EV to EBITDA ratio is 6.25, with an EV/FCF ratio of 7.90.
EV to Sales3.21
EV to EBITDA6.25
EV to Free Cash Flow7.90
EV to Operating Cash Flow7.80
Balance Sheet
PTC Therapeutics has $1.89B in cash and marketable securities with $395.09M in debt, giving a net cash position of $1.50B billion.
Cash & Marketable Securities$1.89B
Total Debt$395.09M
Net Cash$1.50B
Net Cash Per Share$18.05
Tangible Book Value Per Share-$8.50
Margins
Gross margin is 77.84%, with operating margin of 49.49%, and net profit margin of 39.44%.
Gross Margin77.84%
Operating Margin49.49%
Pretax Margin40.25%
Net Profit Margin39.44%
EBITDA Margin51.29%
EBIT Margin49.05%
Analyst Forecast
The average price target for PTC Therapeutics is $93.10, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$93.10
Price Target Upside28.54% Upside
Analyst ConsensusStrong Buy
Analyst Count13
Revenue Growth Forecast-53.34%
EPS Growth Forecast-130.87%